Archives of Internal Medicine · 1946 · 68 citations · 15 references
Antimicrobial ChemotherapyDigestive TractMicroorganism Actinomyces GriseusBacterial PathogensDrug ResistanceInfection ControlDrug AbsorptionAntimicrobial ResistanceAerobic CulturingHealth SciencesAntimicrobial Drug DiscoveryAntibiotic SubstanceAntibacterial AgentAntimicrobial PharmacokineticsAntimicrobial CompoundPharmacologyClinical MicrobiologyJanuary 1944Antimicrobial SusceptibilityAntibioticsMicrobiologyAntimicrobial PharmacodynamicsMedicine
Streptomycin, an antibiotic substance obtained from the microorganism Actinomyces griseus, was described in January 1944 by Schatz, Bugie and Waksman.<sup>1</sup>This material was shown to possess activity in vitro over a wide range of bacteria but was of particular interest because it was effective against many bacteria which were not susceptible to the chemotherapeutic substances then available for the treatment of human infections. Subsequent reports have confirmed these observations and, in addition, have shown that streptomycin is effective in the treatment of experimental infections with organisms of the Eberthella and Salmonella groups<sup>2</sup>and with Pseudomonas aeruginosa, Shigella gallinarum, Brucella abortus and Proteus vulgaris,<sup>3</sup>as well as with Pasteurella tularensis<sup>4</sup>and with the Klebsiella organisms.<sup>5</sup>Streptomycin was also found to possess activity against the tubercle bacillus both in vitro<sup>6</sup>and in vivo.<sup>7</sup>The toxicity of a partially purified product for mice was reported to be of a fairly low order
15